Main Menu

FCLL study

Genetic Study of Familial Chronic Lymphocytic Leukaemia and other Lymphoproliferative Disease (FCLL Study)

MREC (99/1/082)

B-cell Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia subtype, constituting about 30% of all leukaemia cases. There is well-documented evidence of familial CLL. This study is site-specific assessment (SSA) exempt.

Run by Professors Richard Houlston and Catovsky, the aims of the study are to ascertain families with multiple cases of CLL in order to map and identify genes predisposing to CLL so that we may be able to develop new treatments for these diseases and/or detect them at an early stage. The researchers are also interested in related B-cell lymphoproliferative disorder’s (LPD’s) (any disorder in which the white cell count is raised) such as Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s disease (HD), and Multiple Myeloma (MM).

Who’s eligible?

Individuals with B-cell CLL, with or without a family history of CLL, and individuals with B-cell Hodgkin’s Lymphoma (HL), Non-Hodgkin’s Lymphoma (NHL: SLVL, SLL, MCL, DLBCL), Multiple Myeloma (MM) are eligible.

Study requirements

We ask for blood and mouthwash samples from study participants.

Study documents for patients can be found on the right.

Contact Us

If you would like to be involved or have any questions please contact the FCLL study co-ordinator on 0208 722 4431 or email [email protected]